<SEC-DOCUMENT>0001193125-17-284367.txt : 20170914
<SEC-HEADER>0001193125-17-284367.hdr.sgml : 20170914
<ACCEPTANCE-DATETIME>20170914060759
ACCESSION NUMBER:		0001193125-17-284367
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170914
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170914
DATE AS OF CHANGE:		20170914

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LivaNova PLC
		CENTRAL INDEX KEY:			0001639691
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				981268150
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37599
		FILM NUMBER:		171084568

	BUSINESS ADDRESS:	
		STREET 1:		20 EASTBOURNE TERRACE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W2 6LG
		BUSINESS PHONE:		4402033250662

	MAIL ADDRESS:	
		STREET 1:		20 EASTBOURNE TERRACE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W2 6LG

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sand Holdco Plc
		DATE OF NAME CHANGE:	20150420

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sand Holdco Ltd
		DATE OF NAME CHANGE:	20150415
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d420446d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported):
September&nbsp;14, 2017 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g420446g66c94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>LivaNova PLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-37599</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>98-1268150</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>20 Eastbourne Terrace </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>London, W2 6LG </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>United
Kingdom </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>+44 20 33250660 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or
Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).c</TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">this chapter). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Emerging growth
company&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;14, 2017, LivaNova PLC
(&#147;<I>LivaNova</I>&#148; or the &#147;<I>Company</I>&#148;) issued a press release announcing that the Company is exploring strategic options for its Cardiac Rhythm Management (CRM) Business Franchise as part of the Company&#146;s ongoing
efforts to strengthen LivaNova&#146;s position as a leading, innovative medical device company dedicated to extending and improving the lives of patients around the world. A copy of the Company&#146;s press release is furnished as Exhibit 99.1 to
this Current Report on Form 8-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information disclosed under this Item&nbsp;7.01 shall not be deemed &#147;filed&#148; for any
purpose, including for the purposes of Section&nbsp;18 of the United States Securities Exchange Act of 1934, as amended (the &#147;<I>Exchange Act</I>&#148;), or otherwise subject to the liabilities of that section. The information in this
Item&nbsp;7.01 shall not be deemed incorporated by reference into any filing under the Exchange Act or the United States Securities Act of 1933, as amended, regardless of any general incorporation language in such filing. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(d) Exhibits </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d420446dex991.htm">Press Release, dated September&nbsp;14, 2017. </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">LivaNova PLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: September&nbsp;14, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Catherine Moroz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Catherine Moroz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Company Secretary</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated September&nbsp;14, 2017.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d420446dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g420446g66c94.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>NEWS RELEASE</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LivaNova to Explore Strategic Options for </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cardiac Rhythm Management Business Franchise </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>London, September</B><B></B><B>&nbsp;14, 2017 &#150; </B>LivaNova PLC (NASDAQ:LIVN) (&#147;LivaNova&#148; or the &#147;Company&#148;), a market-leading
medical technology and innovation company, today announced it is exploring strategic options for its Cardiac Rhythm Management (&#147;CRM&#148;) Business Franchise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;As part of our ongoing efforts to position LivaNova for long-term success, we are sharpening our focus on the Company&#146;s areas of strength and
market leadership. To that end, we are exploring options to realize the full value of the CRM Business Franchise,&#148; said Damien McDonald, Chief Executive Officer. &#147;The CRM Business Franchise is a global business and strong regional player
with attractive assets, a robust pipeline and growth potential; however, it is no longer a strategic fit within LivaNova&#146;s portfolio. The Board and executive leadership team are committed to driving value for shareholders and customers and will
continue to take actions that strengthen LivaNova&#146;s position as a leading, innovative medical device company dedicated to extending and improving the lives of patients around the world.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CRM generated $249.1&nbsp;million in net sales for the full-year 2016 and is focused on the development, manufacturing and marketing of products for the
diagnosis, treatment and management of heart rhythm disorders and heart failure. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and <FONT STYLE="white-space:nowrap">low-voltage</FONT> pacemakers. Its
innovative technologies have helped position the CRM Business Franchise as a market leader in Europe and Japan. These technologies include the KORA 250<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, the world&#146;s smallest full-body
MRI conditional pacemaker, and PLATINIUM<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a range of implantable cardiac defibrillators and cardiac resynchronization therapy devices that offer unmatched battery longevity<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company noted there can be no assurances that the process of exploring strategic options for the
CRM Business Franchise to maximize shareholder value will result in a transaction or that any transaction will be consummated. The Company has not set a timeline for completion of the review process, and it does not intend to disclose further
developments unless or until a definitive decision has been reached by the Company or the Company has otherwise determined that further disclosure is appropriate or required. For the time being, the Company expects to continue to operate the CRM
Business Franchise in the normal course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barclays is serving as LivaNova&#146;s financial advisor to assist in the evaluation process. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Medtronic Evera&#153; XT VR DVBB2D4 Device manual M957115A001A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-01-03.</FONT></FONT> Medtronic Evera&#153; XT DR DDBB2D4 Device manual
M957111A001A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-01-03.</FONT></FONT> Medtronic Viva&#153; QUAD XT <FONT STYLE="white-space:nowrap">CRT-D</FONT> DTBA2QQ Device manual M956933A001A <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">2013-12-05.</FONT></FONT> Biotronik IperiaTM&nbsp;5/7 <FONT STYLE="white-space:nowrap">VR-T,</FONT> <FONT STYLE="white-space:nowrap">VR-T</FONT> DX, <FONT STYLE="white-space:nowrap">DR-T,</FONT> <FONT
STYLE="white-space:nowrap">HF-T,</FONT> <FONT STYLE="white-space:nowrap">HF-T</FONT> QP (ProMRI&reg;) Technical Manual 403736 Revision: B <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(2014-11-19).</FONT></FONT> St. Jude Medical
- Bradycardia and Tachycardia Devices - Help Manual -&nbsp;June 2013&nbsp;Art 60033180/A.&nbsp;Boston Scientific - Physician&#146;s technical manual AutogenTM&nbsp;EL ICD, AutogenTM&nbsp;Mini ICD, DynagenTM&nbsp;EL ICD, DynagenTMMini ICD,
InogenTM&nbsp;EL ICD, InogenTM&nbsp;Mini ICD, OrigenTM&nbsp;EL ICD, OrigenTM&nbsp;Mini ICD - Implantable Cardiovertor Defibrillator - <FONT STYLE="white-space:nowrap">359060-001</FONT> EN Europe
<FONT STYLE="white-space:nowrap">2013-04.&nbsp;Boston</FONT> Scientific&nbsp;- Physician&#146;s technical manual <FONT STYLE="white-space:nowrap">AutogenTM&nbsp;CRT-D,</FONT> AutogenTM&nbsp;X4 <FONT STYLE="white-space:nowrap">CRT-D,</FONT> <FONT
STYLE="white-space:nowrap">DynegenTM&nbsp;CRT-D,</FONT> DynagenTM&nbsp;X4 <FONT STYLE="white-space:nowrap">CRT-D,</FONT> <FONT STYLE="white-space:nowrap">InogenTM&nbsp;CRT-D,</FONT> InogenTM&nbsp;X4 <FONT STYLE="white-space:nowrap">CRT-D,</FONT> <FONT
STYLE="white-space:nowrap">OrigenTM&nbsp;CRT-D,</FONT> OrigenTM&nbsp;X4 <FONT STYLE="white-space:nowrap">CRT-D</FONT> Cardiac resynchronization therapy Defibrillator <FONT STYLE="white-space:nowrap">359059-019</FONT> EN Europe <FONT
STYLE="white-space:nowrap">2013-04.</FONT> </I></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About LivaNova </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients
around the world. LivaNova&#146;s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than
100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy),
Houston&nbsp;(U.S.A.) and Clamart (France), respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For more information, please visit </B><B><U>www.livanova.com</U></B>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of Section&nbsp;27A of the United States Securities Act of 1933, as amended, and Section&nbsp;21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not
historical facts but are based on certain assumptions of management and describe the Company&#146;s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology,
including, but not limited to, &#147;may,&#148; &#147;could,&#148; &#147;seek,&#148; &#147;guidance,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;likely,&#148; &#147;believe,&#148; &#147;will,&#148; &#147;expect,&#148;
&#147;anticipate,&#148; &#147;estimate,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;forecast,&#148; or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements
contained in this press release are based on information presently available to LivaNova and assumptions that the Company believes to be reasonable, but are inherently uncertain. As a result, the Company&#146;s actual results, performance or
achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance or actions that may be taken by the Company and involve known and unknown risks, uncertainties and
other factors that are, in some cases, beyond the Company&#146;s control. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning the exploration of strategic
opportunities for LivaNova&#146;s CRM Business Franchise, the likelihood or the timing of any resulting transaction, or the ongoing operation of the CRM Business Franchise while such strategic opportunities are being explored. Important factors that
may cause actual results to differ include, but are not limited to: (i)&nbsp;reductions in customer spending, a slowdown in customer payments and changes in customer demand for products and services from the CRM Business Franchise; (ii)&nbsp;the
ability to hire and retain key personnel for the CRM Business Franchise; and (iii)&nbsp;the ability to attract new customers and retain existing customers of the CRM Business Franchise in the manner anticipated. The foregoing list of factors is not
exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company&#146;s business, including those described in the &#147;Risk Factors&#148; section of LivaNova&#146;s Annual Reports on
Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and other documents filed from time to time with the
United States Securities and Exchange Commission. LivaNova does not give any assurance (1)&nbsp;that LivaNova will achieve its expectations, or (2)&nbsp;concerning any result or the timing thereof, in each case, with respect to any regulatory
action, administrative proceedings, government investigations, litigation, warning letters, consent decree, cost reductions, business strategies, earnings or revenue trends or future financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All information in this press release is as of the date of its release. The Company does not undertake or assume any obligation to update publicly any of the
forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.
If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking
statements, which are made only as of the date of this press release. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LivaNova PLC Investor Relations and Media </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Karen King, </B>+1 (281) <FONT STYLE="white-space:nowrap">228-7262</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deanna Wilke,</B> +1 (281) <FONT STYLE="white-space:nowrap">727-2764</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate External Communications Manager </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>corporate.communications@livanova.com </U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact
(General) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andy Brimmer / Sharon Stern / Ed Trissel / Matthew Gross / Jeffrey Kauth </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joele Frank, Wilkinson Brimmer Katcher </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) <FONT
STYLE="white-space:nowrap">355-4449</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">LIVN-jf@joelefrank.com</FONT> </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact (France) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alexis Volanov </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Volanov </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+33 6 16 58 31 10 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>alexis.volanov@volanov.com </U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact (Italy)
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luigi Norsa </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luigi Norsa&nbsp;&amp; Associati S.r.L.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+39 335 710 47 51 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>luigi@luiginorsa.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g420446g66c94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g420446g66c94.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( #, KP,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /</V2)/V/V^._A8?"2R^,L/CU=.\3+IDGC"73VT!+7^QKG^
MU!=?9I2=YLHY&A '^L=/I7W>?1XB66R_M!X:6&C57O0OS;V]VRTUM>]C[O/5
MQ#_9LO[0EAY8:-5>]!2YG_ATT\[V/V,KX0^$/"/VE_ &O_%+X(^/O 'A:.RE
M\0>)-+M+33(]0NOL=D9K?5].OV,\^"(U\JTD .#R0.]=V5XJG@<QP>+JN48T
M9W?+Z=NYWY7B:>"Q^%Q51R4*$[OE]#YO_88_9T^)/[/T7Q+3XB6VC0OXJN/"
M\NE_V3JJ:J2-%@UE+U[A8HD\IF;4+?;][(CKV.)LZPN;5<-+#1DE0]IS.2=[
MMW7X=OS/6XDSC#9K/#/#QDE0]I=R3OK+F7]+\S] U90 "2, #Y@1R ,\X S]
M*^837I;R:V]3YE.^W3R:V];#MR@#G XQVSGH![^U.ZM>]E]PUMH!=5ZG:!Z\
M#\S2NDTKJ\ME?L"W26[V0!E/W3G!QQV(ZCZBBZU5[<NC#O\ W= #+D@')7J!
MSCM3VT\K_(-M/*_R/(?C[X3U7Q_\%OB=X)\/&S_MSQ-X-UG1]+&H7"V5F+V\
MM3'!]JN9%*V\.]ER[#BN[*\13PF883$U$W3P]:$IJ/Q63O9+O;8[LKQ%/"YA
MA,343=/#UH2FHKWK)WLEWML?S_?%/]E#XR?!3PU%XW\50:*VB0:KI^GOJ?AG
M78-6FT>^N"7TZ\O$MHU:U1KZ/$=PQ")*D2GF1<_J& S_ "_,:ZPN'IU/:SC)
MP4U92M9-1OHW9_@?I^"S_+LPK+#4(5%5E&3@IJRDU9-1[M)_F?M=^QS\>H?C
ME\)-/OM3N8O^$W\*?9_#WC.WW?O)[VW@06.NHI)8VVI6H63?T%Q%=1C_ %?/
MYWGN5O+,?4IPUH5G*5.2T5U;GBO\#:3^1^>9YE;RS'5(P][#UW*=*2^%M6]I
M%?X&TG\K'PM_P54(/B'X.D=/[$\7^W2]T<5]+P3\&/\ )P_,^DX*^#'>3@?H
M9^R,1_PS7\'/;P=:_I=7?^%?)9YIF^8^567YGRF=Z9MF'E5E^:/HX,.V<?0_
MAVKS$U:ZV7];'EIZ>2_K8"RKC)V\X&>,GT'O1=:+;MT&GTV[= WKQ@Y!Z$ L
M/3J :>W96\T.WRMYH-R^O\^W7\J2:L[/2.XEUMM'< R]CGZ D#C/4#T_SS0V
MHZ;?)BO;3MY!N7UQC ]"">@QZ^U/;R'M;IV LJ]\8] 3C'KCIVHZVV_X +>W
M5"AAQCGC(P"1@].>E)-=!)KH?F!^S=X^_:_USXP>'--^+GPFM/"O@.>SUUK_
M %N'X96WAV2SNX]+FFTV)=7BO96M5FNEC@*[/WHDQD5]AG&'X=I8&4\!BY5L
M6ZB_=O$2GR[:\KIKFTOO)>I]CG%#A^E@)3P./J5\7*HE[)UY24=5JTZ:YM.[
MOY]_U KY ^//G+]K;5M6T#]G7XJ:SH6IW^BZOI_AZ*6RU32[RXL-0LI#JNG1
MM+:7=M(DD$OEO(H92#\U>GDL*=3-,%2JQ4J<JBO%I6V?<]3)81J9I@J52*E3
ME45XM>3/A']@O4O'?Q@^'7[1?AOQ/\1/&^H:A=VOAC3= UV_\6:Y=:IX=N]0
MTWQ+Y%WI-[->M-ITJW]M9S.T#Q>9Y2JPP,U]-Q12PN7X[+9T<+3A3BYRG!12
M4U&:T:TOHK'TO$U/#8#&Y;.EA:<*<93E."BK349JZ:TOI=6V/*OV-?CC\2O"
MG[1S_#+XJ>,_%>MPZ\VL>!;JQ\5>(-4U:#2O%VESRMILMDFI7,OV:6ZN+&>U
M+*<LMPIQR*[.(,MPF)R>./P>&C0G3]G4DH))<LTI-+E_E3UVM8[,^R_"8C)U
MCL)AHT)P<*CY$DN6:4FE;^5/7;8^W/V__C%J?PN^#=MI'AO6K[0O%GCS7;?2
M=-U#3+RXL-6L-(TQEU/7+ZQNK1TEM90JV=F948,!J&5R5-?/<+Y?''9B_:TH
MU:%"+YHSCSP?.N57BVOA;OZJ_2Q\]PQE\,=F$O;TE4H4(MR3^!\ZY8Z].5N^
MW0\)^ 'Q1\5_ _\ 93\6?M ?%+Q)XO\ &^K>,-<73? 6A^)_$6JZO$X@:;3]
M*AMCJ%S(+6WN=1CU6XN9$7>]OI0978NH'HYM@\-F>>TLLP-"CA:&$IOVDJ=-
M4V_9KFG?E;OHDHWMJ];'H9I@\+F6>0RS 4*>$H86G+VDH]?9J\K-)[I6C>VK
MU/EGP:G[8_[7NM:QK^@^,==@TS3KM5NKU?$E]X0\%Z+>/^_CT?2[;3)5^T7-
MO'*@PD=Q,(_+:9R6%>WB7P_D%*EAZT*4I\L7RRP\*M5W5[MRE&R\K[^I[6(>
M09!2I8;$4Z4ZG+&5G0A5J>\KIMRE&R\N_J87QD\>?M;_  @M],^$7Q*\9^,-
M)ET^]E\0>'_$>F^*-1%]JVERVLEE/:Q>)["YCEU?24NPD@AO6:6VE!&U00:U
MRW"9#CYO'8;"TZKJ_NY4Y14.67\WLXN481M;9W\CHRW"9#CYO'X;"TZCJ_NW
M3DE#EE_-[.+E&,;6V=S]+?AEYOQ"_8 MAXZ\>S:*WB+X;>*[;7OB)XGN[W5Y
M=*@;7-:@_MC5;B:[2YO$MK>*-3FZ0[(@H8#I\CBXQP?%,H8?#.I&AB(.%&E:
M,I-)6A%N,DKO:\7Z'R&*2PG%$HX?#.I&AB(.%&DU&4K)6A%N+2;:W:?H>1_L
MF_L_?"1O^%P^%;/X[^%?CCIOCCP-IVA>(-$T*RN+:?0K)KZZDMM88W.LWPW?
M:6C-L52-HY;-6W.5&._B#,\RYLMQ%7+*V5SPLN:DYSBXSM_=5*F[M7UN]+JV
MMSOX@S+,7_9U>MEE;*Y8:7-2E.<7&=MO=5*F[V6]WI=6UNOCSX5>*/$G[%'[
M3>H>&_%<EP/#BWX\,>+P%=;75?".H2)+HWBZWA09D-J)(;Q0F?OWD0&0P'OY
MC0H<2Y1'$TH\M?D4NB<)Q5IK2]N?[]/(]S'T:/$63PKP2C74%+LX32]]:7MS
M?ITL>]_\%1[B&]U;X+W=K-%<6L_A[Q5<6]Q#(LD5Q;SW6BRP30NIQ)&\3*RL
MO!!![UY7!,91CF,9+EE"48M/^Z['F<%*45F$9+EE"4(M>FA]I?!KXC:%\)/V
M*_ ?Q!\1%QI?AKX>PW;6Z,B37]T]Y=06&G6[.0HGNKR2&%2>GF9P<8KYO'X2
MIC>(,9A:2?-4K25U]E*6K^2U/G<=A:F-X@Q>&I)\U2LTW_+'FU?R5S\QH/'W
M[7W[9?B_5H_!6HZUIFCZ:RRRZ)X>UR3PEX/\,6LI9K&VU6_6>*35=1: AR;B
M6=Y=C-!%&HK[-X3(>',/1>+A]8KRNN::_>;6OR*ZL_73<^RGA<AX<H4)8J"Q
M5:5_>FE[175F^2]K/UTW&3^//VN_V-O&6E0>,M4UK4-(OG::'1_$&N2^+/!W
MBBQMV7[=:Z9J+W$KZ9?*IX$<L4\+%6>-D.*(X3A[B'#5UA?<JQA*7+&/+4AR
M[MKLWHK/7R".$X?XAPU187W:JVC"*4X:V3:_E;TT;]#Z1_; \=^*_''P7^%'
M[2?P=\<>./#'A^_C;0/%.D^'_%.K:9#92:A)*;*74+;3+R*V>\L-8@O=->=H
M]SK>6VX@1*!Y/#V$H8?-:^2X[#4*SB_W=2M24W;DC)+F;32LT[6?O7/(X?PN
M'PN9ULEQV&H5VI-4YU:2F[)*RNVFEU22>K9]7?L-_%Z]^+'P,T@ZWJ=SJGBO
MP9?S>%/$=[>W,EWJ%\8"MWI.IWTTQ+RSW>EW4.^1CEF@<GDX'A\18%8',JD(
M4XTJ%;WZ:C'D@DO=<8QZ:QO97WWU/&XBP"P.95(0A"E0K+GIJ$>2"2]UQC'I
MJKV5]]]3\^?V@_BS\3_B]^UH?A?\+?'WC+PYH\/B#2?AS90>%O$NKZ192W5E
M/Y?BC6IX=-N$7S;><Z@GG%2!%IRR#*DD?593E^#P/#_U_%X:-:K*%2JN=)NT
M$[1UVD]++\3Z?*<!@\#D/UW%8:-2LZ=2K[Z6D8)M15]I-6M^9[/^VG^U7XK^
M&6IV'P'^$NKWMAK.DZ+I:>*_&*2F^\1++<V<26&CV-Q<"5EU.:Q,5W<W;!I=
MUW L3!R37G\.9'A<;&KF>803ISJM0AJH0CK>4]%:,;6TN>?P[DF&QJJYCCH7
MA*H^2"TA".O-.>BM&-K:7]#Q#1/@)^WQHFBV_P 4=*\5^*X=5@ABUV+PY=?$
M&[OO$LT,4!NUCO-!U&XGL[\O;M+&^G7,DDI,V-@*J!WULTX7K599?+ J-*4O
M9*O!)1C)62DY-IJ/6Z3?D=]7,^&*M2> G@5&D[TXUX)<JE'9\W,G9]&D>*^"
M_C[\9?&7QHTV]U7X@^-;*/7M7U^[O?#UIXGU^RT.TN(_#6LM):V^C2WC165I
M%=6@D2T6)5BD (QM%>GC,IR_#9;45'"THNA&FU-*_-%U(PYE)J[O?[CT\5E>
M7T,KE['"TX^RC3DI)7<HNI&"=VKN]S]!OV>/!W[5OA7XLZ%K7QA^,ND:_P##
MZSLM=35M)D^)=GK"W%U=Z9+%I<QTXA _E:B864EOW87CBOD<TQ.1U\$X9=E\
MZ.*E)-S]G;;[.FB5NQ\GF>)R.O@W3R_ 5*6*E)2<_9_^2Z*RT['Z0_\ "5>&
MA_S,.@C'_48TX8_\F:^7]E57_+F>G]UGRWLJJ_Y<S_\  6?.O[7FIZ?J7[,'
MQD?3[^QOEA\-P+*UE=P7:Q,VKZ:561H)&",0,@''2O3R2,H9Q@.:#A^\5KJW
M<]3(XRAFV!YH.'[Q6NK=&?&?_!*H?\2_XX=L:EX ..P86GBOYC[X"CVVU]+Q
MRK5LNZ6C6_\ 3B/HN-G^^R]6M95M?^W_ -#Q;_@H+\.]0^%7QVT#XN^&5:TM
MO&CVGB.UN8T(2P\=>$YK9[LJ1@>;=0QZ7=8)^;%P!QNKOX6QBQF65LNJVE.A
M>,8O[<)KE5^R@GI;L>APOBUC,LK9=5M*="ZC%_;A-<JOV4+Z6['GO[0WQ.O?
MVN_C=\-/#_A 7#6USH_A/PGIMJPV"T\0^(1;ZCXJNV0G#?9)9Y(6E&!MTQLG
M:5KJRC"1R#*\=5Q#]E64ZDNEN6*?L]=_>:7I?0Z,JPJR'*\=5Q'N554J-KIR
MQ7[O7=7=OO/LO_@H?X+3PC^SC\*M"\.QF#PIX)\4:+H$]O&C+'Y*:%<66F32
M '",9K65C(<_/<8SF0Y^=X3Q"K9KBI5FE6Q<7RN^JYIZ\M]]$EZ'SW"U>-?-
M<5*JTJF+B^5]8\TM>6_9=^AZC_P3CUW0+_\ 9WM=#TZ:V&N>'?%?B4>(K-&0
MWD=QJ6H-?Z==7$2_,R-I<UO;).<*?L;*"=A Y>,*=:GG%2K42C&I"'+HVHJ*
MY$E_X#?U;Z'-Q;3JTLWJU*J2C4C!QT;45%<B2_\  >;U;Z'S_P#\%2-=T"8?
M"?PQ');2>)K*7Q'J]Q"CJUU8Z->1:?;0)=1@GRX[J[MC(I<@8T^3C$H)]/@B
MC453&8B2:H<JBY;>]=^]!=UYGJ<$TZJJ8VNTU0Y>5O;6[]Z"V;1[M\&?^$0'
M_!.W3?\ A/H-=NO!8^&GBT^)K?PP(O\ A()M'&OZ\;Q-&$SJGV_RQ^[W,HSC
M)KSLP]JN+:GU?V?MEB*?L_;)NGS65O:)7;CW2/-Q_M5Q74^KNFJWMZ?(ZJ;I
M\UM.=*[Y>]D<]^PL?V:CXN\?CX%Z5\7=/U9O#FBOX@E^)+6;64VG#4KHV7]E
M);74ICO/M1F,NY8\@*<5IQ,LV]E@_P"TYX.7Q>S^K*2FEKI)N,59=M[V-.)8
M9JJ6$>9U,'+?V?U924U&ST;<(KE75;WL6/\ @HG\ #XY\ V_Q8\.67G^*?AU
M:R_VY#;P[I]7\%,[2W7R1_-)/I5RWVM",E8);S'&!4\)YK]2QGU2M4MA\3:]
M]DTFEY:WU\_4GA3-%@\8L+B)7P^(TUO9-)Z=M;_?ZGY"^-_BSK'CWP#\+?!V
MNAKFY^%MGK^CZ7J[R!Y;W0-4GL9]+LI0Q+>=9I;36R,W6&"(DDU]_A,N6#Q>
M,Q%)*-+&.#Y5]GE27,O\6[\S[W"Y:L%B\7B*45&CBW!\JVCRJUUYRW?F?I5\
M6+#4KW_@FG\.9+%)&@T^T\%WVJ1(<@Z?%KMW$)97Y46\-U-:3,S#&$&:^*RZ
M<8<88N?-R)RKQ5[;ZI6\[['QF734.+L7*ZBN:O'7[M//JO4[?_@F1X@\/2_"
MCQ?X8M;JW3Q58>,[G6=6L@RKJ%SI.IV%C%I5Z(W423VRO:7<?F?,$)56"E@#
MGQI2K+'X?%-?N*E&$(S:;C&4%[W,EM)K2W^1'&5*LLPP^(:2P]2A&$)--Q4H
M+WN:VS?YV["?\%/-=\-P_"_P3X9GEM7\5WWC2'5]+M R&]M]+L-/O8M5OVA4
M[H;:02P6XF8!69@H))XC@VE6GC<1.DG"G[+DE*UHM2DD[-]5O;RU(X/I8CZY
M6J4DXTE&"E*S4=)K9]7Y>1;_ &/?AB/B/^Q+KG@3Q$FW2_'>H^-4T9IXRJVL
M<EPB:?JELK=(XM;M!.I3C*-C[U'$6-6&XD^M4&KX?V2E9VUBN5IV[Q2;]2,^
MQBPO$3Q-)IN@XWL[*]W=.WDSX-_9D^.&I?LM^+?C!H7B:.XMWG\,>(=(%BR;
MO*^(GAA[E=!\R)LJS27+75JS8 *2Q$G8HKZ;.L!'/,/EE6@DW&K'F>G\)I-N
M_D[VZ:'T^=8!9UA\LJ4+/EJQN]/X4DG)W\I7MTT/=/\ @FG\-KGQ3\0_&GQG
MUU#<?\(O%-H^GWD^9#/XJ\2!KG6+A7;_ %DEOIDC1;QDJ-1VYKS.,,8J&#PN
M6T79R?M)Q7V8QTY5;H]]==#S>+\4J&&P^7T96]I[\DOLQBK<JMO%_>>)_&J:
M#P?^W?JNL>-?^01I_P 7O"GB:_-UAH?^$9DN]&O;5V63B6U73D0,.5Q;LA^4
M5Z66I5N%E2P\E"?L*D9/^]_GV/0RR];AI4L,^6;P]6,G'>^E_GH?T#B^M&M8
M]1%S;MI[6_V\7ZS(UHUD1]H6]6Y#;#;FUQ(9 =H3G=@5^4J*YW0LHU&[>SM*
M[E?1I]^_G9'Y8X.4_8<KIU%)6IM.[DGIROSZ^=D?S7Z?JVC:]^U1JNM^'3&V
MAZM\0/B)J.E20\PSV5WI7BF:&ZA.U<Q3J_G+QPLP4\J<?L,X5*>01IU;JI##
M8>,E+=-5X:?(_89PJ4\A5.K=5(X?#J2>Z:K0T]%YZGNQ_P"";/[2)ZZM\-SC
MU\8:]V.0/^19Z ]J\Y\69+?^!57IA:*_*J><^+,E_P"?%5>F%H+\JH?\.V?V
MD /^0M\-QCG_ )'#7ATY&?\ BFNF0*:XKR7_ )]5M/\ J&H__+1/BK)GHJ-=
M6_ZAJ/\ \M/JGX5?L@_%[P9^SO\ 'OX6:W>>$)_$_P 2Y=&;PW+::]J-UI4*
M6/EM.-1O)]&CEM/N$*$AFSGJ*\''Y]E]?-,KQ=&%6-'".2FG2A3;;=TER2DG
MIWMV1X..SW 5LTRO%4HU8T<(Y*:=*%-ZNZMR2E?3O9]$CT_]A_\ 9P^(W[.]
MG\2X?B!/X:D;Q9>>$Y](/AW5+G4U5-%MM:BO?MC76FVGDLTFHP!0HD! <Y&!
M7)Q'G&&S>MAGA8RC"@JEU-:ZRYNC?8Y>(LWPN;5L-+"QE&-!5+J6^LKGK7[5
M_P #Y_CW\([_ ,(:.]A!XJT_4K#Q#X3O-3D>WLX]5L7:.6WN[B**5[6TNK">
M[@=EBD(W+\N0"//R/,UE>/I8F47+#UHN%11WM;=+NMUYG#DF9K*\?3Q+BY4*
ML7"HEVMV[JVECY2_9 _8D\<_!WXJ/\0?B;+X5NAHVA7=EX4M] U2YU1XM6U$
MBUO+^Y%SI=F(/+T[[1'&5#\W /!12/=S[B7#YC@UA<%"I&$WRU)54E-Q@U*-
ME'W=UK:SMY'LY[Q)0S#!QPV%A4A[1\M24DK.,'S)75[:KI;S/T0^)7P[\-_%
M#P9K?@/Q7:&[T#Q#:-9WJ(^RYMV3$MI?6,I#>3>6US''*CCNN""I(/R6&Q%;
M!5Z6)P[Y9T'=6[>CN?*X;$5L%6HU\.^65!W5M=/G?\3\<=2_8/\ VH?A5XGN
M[[X*^,([ZQF/V>TUW0/%,O@_Q"UF"7MX=;LIY(8MZ!OF>&XF7))1%#8K] CQ
M3D^-HQCF>%?.EJN1/F>W->UU?:RLM-KL_0(<49/C:,8YEA??BM5RWYG_ #7W
M5]K:+3979?UG_@G?\<O$WAE_$OB+QIH^N_%O6/$%M)J5IK_B/4+W3;?P_'97
M(F>Z\0R:?/+J6M-?K8N(8XEBA@A=1(Y85G0XOR[#XGV5+"3A@J-/3EBE=WT;
M2MIO>[Z+0RH\69?0Q/LJ6%G#!4Z>G+%*[OHVDMM]W\K'Z*?"CX;_ !.^%_[+
MFD_#33&\)2_%/P]X6UNQTMKZ:?4?!YUV[U?4K_3OMTALXY9M-"WL0D'D!L*1
M@GFOE<7C,'C<YJ8VLZD,'5K1Y_9V550MKR7T4ETOH?+8O&83&9Q4QM7VD<'5
MK1YU3LJJA;50OHI=KZ%GX":7^TCI^M:^WQRC^$<>ERZ79KH'_"N+2XM]0.HQ
MW4@OO[4>>UA#V9M_*:)5R5=I >U9YC4R><,.LL^N<\>;G>(E3<+?W>1MJ5[;
M:6OU(S&IDTX8?^S'C%4C?G6(E3<.7^[R:IIV\K7ZGTI?107$$MK=11SVMQ#/
M;W-O*@>*XMY8FCFAE5@0T;1,P92/F!Q7EIN#YHZ."YEWNMON/+BY0?-'1P7,
MN]UM;T/Q)^(W_!-?XIR^-_$\_P --1\##P->:C/=^'8=<UW4M/U>QL;O;/\
MV9>16^A72.;.5G@BE$S%H8X\A3N!_1<!Q?@HX3#K%QKQQ$8J,E"G&4;+1--U
M8N[6ZMH^K/T3 <78%87#_6XUUB(Q49<E.,XV6B:;JQU:WTT?5GZA?"KX3-H?
M[/WA;X._$&TTO5OLO@Z7PMXFL[2:2ZTN[%RUT)TM;F6"*1D$<ZE9?)C='164
M!E%?$8O&<^:5<PPTG']]*I3;T::ES1YHIM:6]Y7:Z'Q.+QCEF=7'X5N+]M*I
M3YE9W3O'FBFUT]Y7:W5S\PO&_P#P3U^-?@'Q1)KOP&\5)JFF&5Y-*D779/"G
MC#1(IW\PV%Q.KK:ZA$G ^T)<1%Q$C/%OYK[;!\69?B</&AF^&2G&3FY1@JE.
MI)WN[23Y>Z4;)=#[/"\59?B*$</FV&]_FE*3C!3I\S3UL[\O:RT3VZ"^!O\
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2NC7O1O4M.2BTI-1YK\L;?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
